Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProxiBlock: Intramuscular Ropivacaine for Hemiparetic Gait
NCT05519592Unknown
- Sponsor
- Hôpital Henri-Mondor
- Start
- Sep 2022
- Primary completion
- May 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Randomised, double-blind trial of ropivacaine hydrochloride liposomal suspension injection in spastic hemiplegia, sponsored by Hôpital Henri-Mondor. Primary endpoint: Change from baseline of the active amplitude of hip flexion, knee flexion and ankle flexion at 14 days. Status: unknown.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
spastic hemiplegia
Beyond the preview
Go deeper on NCT05519592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05519592.